Akers Biosciences Inc (NASDAQ:AKER) Just Reported Decreased Shorts

June 17, 2018 - By Winifred Garcia

Akers Biosciences, Inc. (NASDAQ:AKER) Logo

The stock of Akers Biosciences Inc (NASDAQ:AKER) registered a decrease of 6.69% in short interest. AKER’s total short interest was 9.96M shares in June as published by FINRA. Its down 6.69% from 10.67 million shares, reported previously. With 4.66M shares average volume, it will take short sellers 2 days to cover their AKER’s short positions.

The stock increased 6.16% or $0.0238 during the last trading session, reaching $0.4099. About 2.04 million shares traded. Akers Biosciences, Inc. (NASDAQ:AKER) has declined 59.38% since June 17, 2017 and is downtrending. It has underperformed by 71.95% the S&P500.

Akers Biosciences, Inc., together with its subsidiaries, develops, makes, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and clients in the United States and internationally. The company has market cap of $34.31 million. The companyÂ’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. It currently has negative earnings. The Company’s marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘CheckÂ’, a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app.

More notable recent Akers Biosciences, Inc. (NASDAQ:AKER) news were published by: Globenewswire.com which released: “Akers Biosciences Receives Notice of Delinquent Form 10-Q Filing from Nasdaq” on May 25, 2018, also Nasdaq.com with their article: “Akers Biosciences Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement” published on May 30, 2018, Businesswire.com published: “Bragar Eagel & Squire, PC is Investigating Akers Biosciences, Inc. (AKER) on Behalf of Stockholders and Encourages …” on June 13, 2018. More interesting news about Akers Biosciences, Inc. (NASDAQ:AKER) were released by: Globenewswire.com and their article: “Akers Biosciences Announces a Change to the Board of Directors” published on May 29, 2018 as well as Globenewswire.com‘s news article titled: “EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Akers Biosciences, Inc. – AKER” with publication date: June 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: